Company intelligence / Profile preview

Novolin 30R

Bagsværd, Denmark

Ownership: Private
Employees: ~64000
Development stage: Other

Overview

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. The company is a world leader in diabetes care, holding a dominant position in the global insulin market. Beyond its core focus on diabetes, Novo Nordisk has successfully expanded into obesity management, rare blood disorders, and endocrine diseases. Its portfolio features high-profile treatments such as Ozempic, Wegovy, and the Novolin line of insulin products, including Novolin 30R. The company continues to innovate through its extensive pipeline of biological medicines and protein therapies.

Therapeutic areas: EndocrinologyHematology
Modalities: BiologicPeptidesRecombinant proteinHormoneSmall molecule
Industry: Pharma

Partnerships

Flagship PioneeringGilead SciencesEli Lilly

Beyond the preview

Go deeper on Novolin 30R.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novolin 30R.

Explore the full profile